How to Perform IVIVC for Delayed Release Drug Formulations On-Demand Webinar How to Perform IVIVC for Delayed Release Drug Formulations This webinar showed how to use a time correction factor to establish a meaningful IVIVC…Certara2019 年 8 月 20 日
Population Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Paediatric Population Poster Population Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Paediatric Population Certara2019 年 6 月 24 日
Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV Poster Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV Certara2019 年 6 月 24 日
Optimize Immuno-oncology Drug Discovery and Development Using QSP White Paper 利用 QSP 优化免疫肿瘤药物发现与开发 A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…Certara2019 年 6 月 19 日
Pirana Modeling Workbench Brochure Pirana 建模工作平台 Pirana is a flexible and extendible modeling workbench with an intuitive graphical user interface for…Certara2019 年 5 月 28 日
Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Poster Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Certara2019 年 5 月 2 日
Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Poster Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Certara2019 年 4 月 22 日
Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Poster Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Certara2019 年 4 月 22 日
Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Poster Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Certara2019 年 4 月 22 日
Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Poster Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Certara2019 年 4 月 22 日